PRICE T ROWE ASSOCIATES INC /MD/ - PROTAGONIST THERAPEUTICS INC ownership

PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 153 filers reported holding PROTAGONIST THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.62 and the average weighting 0.3%.

Quarter-by-quarter ownership
PRICE T ROWE ASSOCIATES INC /MD/ ownership history of PROTAGONIST THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$13,879
-39.6%
831,993
+0.0%
0.00%
-33.3%
Q2 2023$22,972
+140.5%
831,693
+100.3%
0.00%
+200.0%
Q1 2023$9,552
-99.9%
415,274
+38.2%
0.00%0.0%
Q1 2022$7,115,000
-44.8%
300,468
-20.3%
0.00%0.0%
Q4 2021$12,898,000
+48.0%
377,132
-23.3%
0.00%0.0%
Q3 2021$8,712,000
-80.3%
491,641
-50.2%
0.00%
-75.0%
Q2 2021$44,263,000
+87.1%
986,254
+8.0%
0.00%
+100.0%
Q1 2021$23,662,000
+38.8%
913,590
+8.1%
0.00%0.0%
Q4 2020$17,043,000
+48.8%
845,395
+44.3%
0.00%
+100.0%
Q3 2020$11,454,000
-13.2%
585,859
-21.6%
0.00%
-50.0%
Q2 2020$13,203,000
+4286.4%
747,634
+1654.4%
0.00%
Q1 2020$301,000
+0.3%
42,616
+0.2%
0.00%
Q4 2019$300,000
-8.8%
42,516
+55.4%
0.00%
Q3 2019$329,000
+39.4%
27,365
+40.4%
0.00%
Q2 2019$236,000
+57.3%
19,486
+63.7%
0.00%
Q1 2019$150,000
+5.6%
11,900
-43.6%
0.00%
Q4 2018$142,000
-16.5%
21,100
+27.9%
0.00%
Q3 2018$170,000
+53.2%
16,5000.0%0.00%
Q2 2018$111,000
-21.8%
16,500
-0.3%
0.00%
Q1 2018$142,000
-30.4%
16,543
+68.4%
0.00%
Q4 2017$204,0009,8210.00%
Other shareholders
PROTAGONIST THERAPEUTICS INC shareholders Q4 2021
NameSharesValueWeighting ↓
JOHNSON & JOHNSON 2,449,183$43,400,0003.81%
BVF INC/IL 3,901,759$69,139,0002.70%
COMMODORE CAPITAL LP 498,079$8,826,0002.33%
Altium Capital Management LP 346,000$6,131,0001.61%
Twin Lakes Capital Management, LLC 139,287$2,468,0001.45%
Opaleye Management Inc. 330,222$5,852,0001.09%
EcoR1 Capital, LLC 1,443,800$25,584,0000.89%
OBERMEYER WOOD INVESTMENT COUNSEL, LLLP 776,689$13,763,0000.76%
JABODON PT CO 90,656$1,606,0000.66%
Artal Group S.A. 1,500,000$26,580,0000.60%
View complete list of PROTAGONIST THERAPEUTICS INC shareholders